Work

Alterations in serum bilirubin during enasidenib treatment in patients with or without UGT1A1 mutations.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.e19003

Authors: Amir Tahmasb Fathi, Courtney Denton Dinardo, Irina Kline, Nora Tu, Eyal C. Attar, Eytan M. Stein, Stéphane de Botton, on behalf of the AG221-C-001 Study Investigators

Institutions: Harvard University, Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center, Celgene (United States), Agios Pharmaceuticals (United States), Memorial Sloan Kettering Cancer Center, Inserm, Institut Gustave Roussy

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891639496

Cites:

Cited by: 6

Related to: 10